Source: Pharmaphorum

GSK: GSK's Jemperli/TIM-3 immuno-oncology combo moves to ph3

GSK's latecomer to the PD-1/PD-L1 inhibitor category Jemperli has barely started to bring in revenues, and is aThe post GSK's Jemperli/TIM-3 immuno-oncology combo moves to ph3 appeared first on .

Read full article »
Annual Revenue
$42.3B
Employees
90,096
Dame Emma Walmsley's photo - CEO of GSK

CEO

Dame Emma Walmsley

CEO Approval Rating

67/100

Read more